BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Dec. 19, 2007
View Archived Issues
BioMS Signs $497M Deal With Lilly For SPMS Drug
Shares of BioMS Medical Corp. jumped 38 percent Tuesday after the company unveiled plans to license its Phase III multiple sclerosis drug MBP8298 to Eli Lilly and Co. in a deal potentially worth more than $497 million. (BioWorld Today)
Read More
CovX's Peptide-Antibody Bid Attracts Acquisition By Pfizer
Read More
Positive Data In Alzheimer's Send EPIX's Shares Soaring
Read More
Santaris Raises 20M For LNA-Based Drug Portfolio
Read More
ActivBiotics Selling Assets In Wake Of Rifalazil Failure
Read More
HGS's Anthrax Drug, ABthrax, Positive In Two Animal Studies
Read More
Other News To Note
Read More
Clinic Roundup
Read More